上市公司独立董事候选人声明与承诺 声明人赵尘作为四川港通医疗设备集团股份有限公司第四届董 事会独立董事候选人，已充分了解并同意由提名人四川港通医疗设 备集团股份有限公司董事会提名为四川港通医疗设备集团股份有限 公司（以下简称该公司）第四届董事会独立董事候选人。现公开声 明和保证，本人与该公司之间不存在任何影响本人独立性的关系， 且符合相关法律、行政法规、部门规章、规范性文件和深圳证券交 易所业务规则对独立董事候选人任职资格及独立性的要求，具体声 明并承诺如下事项： 一、本人已经通过四川港通医疗设备集团股份有限公司第四届 董事会提名委员会或者独立董事专门会议资格审查，提名人与本人 不存在利害关系或者其他可能影响独立履职情形的密切关系。 ☑是 □否 如否，请详细说明：______________________________ 二、本人不存在《中华人民共和国公司法》第一百四十六条等 规定不得担任公司董事的情形。 五、本人已经参加培训并取得证券交易所认可的相关培训证明 材料（如有）。 ☑是 □否 ☑是 □否 如否，请详细说明：______________________________ 三、本人符合中国证监会《上市 ...

四川港通医疗设备集团股份有限公司 2023年度独立董事年度述职报告 根据《公司法》《证券法》《上市公司治理准则》等法律法规及《公司章程 》《独立董事工作制度》等规定，就2023年1月1日至2023年12月29日期间，本人 陈启明任职四川港通医疗设备集团股份有限公司（以下简称"公司"）独立董事 的履职情况做述职报告。具体如下： 一、个人基本情况 陈启明，男，中国国籍，无境外永久居留权，1989年出生，博士研究生学历 、电子科技大学博士后。2020 年 5 月至今，担任成都朴为科技有限公司总经理 。本人任职公司独立董事，任职期间不存在影响独立性的情形。 二、2023年度履职概况 四、总体评价和建议 在2023年度任职期间，本人对公司2023年度预计关联交易事项发表了独立意 见。本人认为：公司2023年度预计关联交易遵循公平、公正、自愿的原则，不存 在损害公司及股东利益的情形；公司没有对关联方形成重大依赖，关联交易对发 行人财务状况和经营成果没有重大影响、对公司正常生产经营和独立运作没有造 成实质性影响。 （二）定期报告相关事项 在2023年度任职期间，公司编制并披露了《2023年半年度报告》《2023年第 三季度 ...

关于四川港通医疗设备集团股份有限公司 非经营性资金占用及其他关联 资金往来的专项说明 致同会计师事务所（特殊普通合伙） 目 录 关于四川港通医疗设备集团股份有限公司非经营性资金占用及其 他关联资金往来的专项说明 四川港通医疗设备集团股份有限公司2023 年度非经营性资金占用 及其他关联资金往来情况汇总表 1 致同会计师事务所（特殊普通合伙） 中国北京 朝阳区建国门外大街 22 号 赛特广场 5 层 邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 关于四川港通医疗设备集团股份有限公司 非经营性资金占用及其他关联资金往来的专项说明 致同专字（2024）第 510A008803 号 四川港通医疗设备集团股份有限公司全体股东： 我们接受四川港通医疗设备集团股份有限公司（以下简称"港通医疗公 司"）委托，根据中国注册会计师执业准则审计了港通医疗公司 2023 年 12 月 31 日的合并及公司资产负债表，2023 年度合并及公司利润表、合并及公司现 金流量表、合并及公司股东权益变动表和财务报表附注，并出具了致同审字 （2024 ...

Financial Performance - The company's operating revenue for 2023 was CNY 842,437,861, representing a 9.62% increase compared to CNY 768,525,556 in 2022[24]. - The net profit attributable to shareholders for 2023 was CNY 83,097,173.1, reflecting a 12.40% increase from CNY 73,909,823.0 in 2022[24]. - The net cash flow from operating activities for 2023 was CNY 114,316,658, a significant decrease of 328.92% compared to CNY 49,937,411.1 in 2022[24]. - The total assets at the end of 2023 reached CNY 1,996,714,366.68, marking a 71.63% increase from CNY 1,161,890,043.02 at the end of 2022[24]. - The net assets attributable to shareholders increased by 139.70% to CNY 1,328,730,441.04 from CNY 554,436,498.11 in 2022[24]. - The basic earnings per share for 2023 was CNY 0.9728, a decrease of 1.31% from CNY 0.9855 in 2022[24]. - The company reported a total of CNY 22,469,982.27 in non-recurring gains for 2023, compared to CNY 3,488,743.82 in 2022[31]. - The company reported a significant management change with the passing of Vice General Manager Fan Xiongran on October 27, 2023, due to illness[153]. Dividend Policy - The company plans to distribute a cash dividend of 2.58 RMB per 10 shares to all shareholders, based on a total share capital of 99,239,930 shares after excluding repurchased shares[3]. - The cash dividend proposed is CNY 2.58 per 10 shares, totaling CNY 25,603,901.94, which represents 100% of the profit distribution[175]. Market and Product Development - Future outlook includes expanding their product line in medical equipment, focusing on integrated gas supply systems and advanced purification technologies[19]. - The company aims to enhance its market presence through strategic partnerships and potential acquisitions in the healthcare sector[20]. - The company is investing in R&D for new technologies, particularly in areas like digital subtraction angiography and polymerase chain reaction systems[17]. - The company has a robust pipeline of new products set to launch in the upcoming fiscal year, aimed at addressing emerging healthcare needs[19]. - The company is focusing on expanding its product line, including electric and manual surgical tables, which are crucial for patient positioning during medical procedures[85]. - The company plans to launch three new products in 2024, which are anticipated to contribute an additional 300 million yuan in revenue[196]. Research and Development - The company has a dedicated R&D team with expertise across multiple disciplines, ensuring a strong foundation for innovation and product development[53]. - The company emphasizes technological innovation, with a complete R&D system from design to production, enhancing its core competitiveness[56]. - Investment in R&D increased by 25% in 2023, totaling 200 million yuan, focusing on innovative medical technologies and equipment[196]. - The R&D investment accounted for 3.55% of operating revenue in 2023, compared to 3.44% in 2022[84]. Operational Efficiency - Sichuan Gangtong Medical Equipment Group plans to improve operational efficiency by optimizing supply chain management and production processes[19]. - The company has implemented a performance evaluation and incentive mechanism to motivate its R&D personnel, fostering a culture of innovation[55]. - The company provides comprehensive operation and maintenance services for its medical gas and cleanroom systems, ensuring long-term stability and reliability[47]. Compliance and Governance - The company’s financial report has been confirmed as true, accurate, and complete by the board of directors and senior management[3]. - The company has established a structured governance framework, including a board of directors and supervisory board, which operates independently and adheres to established rules[131]. - The company has not reported any significant discrepancies between its governance practices and the regulations set forth by the China Securities Regulatory Commission[139]. - The company is committed to enhancing corporate governance and transparency, with a focus on improving operational standards and compliance with regulatory requirements in 2024[138]. Market Trends and Demographics - The medical device market in China is projected to grow from CNY 623.5 billion in 2019 to CNY 1,035.8 billion in 2023, reflecting a significant increase in demand for medical services[37]. - The population aged 65 and above in China increased from 123 million in 2011 to 217 million in 2023, accounting for 15.4% of the total population, indicating a growing demand for healthcare services[38]. - The total number of medical consultations in China reached 9.56 billion in 2023, a 52.62% increase from 6.264 billion in 2011, highlighting the rising health service awareness among residents[38]. Risk Management - The report emphasizes the importance of risk awareness regarding future plans and commitments, indicating that investors should understand the differences between plans and commitments[3]. - The company acknowledges the risk of bad debts due to increasing accounts receivable as sales grow, particularly from public hospitals reliant on government funding[125]. - The company is exposed to raw material price fluctuations, which could impact profit margins, and plans to diversify procurement channels to mitigate this risk[126]. - The company faces risks from intensified market competition in the medical gas and clean equipment sectors, with a need to maintain competitive advantages to secure its market position[121]. Shareholder Relations - The company has committed to maintaining compliance with relevant laws and regulations during the repurchase process[190]. - The company will notify the market of any share repurchase plans, including details on price and quantity, within 10 trading days after the stabilization plan is announced[190]. - The company has established a commitment to maintain transparency and accuracy in its financial disclosures post-IPO[193]. - The company has committed to repurchase shares if any fraudulent issuance is confirmed, with the repurchase price not lower than the market price at the time of repurchase[199]. Strategic Partnerships - The company has established strong partnerships with numerous medical institutions, focusing on the sales of medical gas equipment and cleanroom systems, along with related products[46]. - The company is exploring market expansion opportunities through the introduction of innovative medical technologies and devices[85]. Employee Development - The employee training program includes a comprehensive annual plan with targeted professional training courses for different positions[174]. - The company has established a fair and transparent salary incentive mechanism, including basic salary, position salary, and performance bonuses[173].

Financial Performance - The company's revenue for Q1 2024 was CNY 76,119,952.75, representing a 7.40% increase compared to CNY 70,874,328.77 in the same period last year[5] - Net profit attributable to shareholders increased by 75.58% to CNY 10,707,388.40 from CNY 6,098,289.41 year-on-year[5] - The company reported a basic earnings per share of CNY 0.1073, up 31.98% from CNY 0.0813 in the previous year[5] - Operating profit for Q1 2024 was CNY 10,618,920.79, compared to CNY 6,501,060.65 in Q1 2023, marking a growth of 63.5%[21] - Net profit for Q1 2024 reached CNY 10,707,388.40, a significant increase of 75.5% from CNY 6,098,289.41 in Q1 2023[22] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.1073, compared to CNY 0.0813 in Q1 2023, reflecting an increase of 32.5%[22] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to CNY 37,498,382.94, a 169.41% increase from a negative CNY 54,023,970.05 in Q1 2023[8] - Cash flow from operating activities totaled CNY 269,434,763.64 in Q1 2024, compared to CNY 168,284,597.45 in Q1 2023, indicating a growth of 60.1%[23] - The net increase in cash and cash equivalents was CNY 54,495,877.02, a 368.52% rise compared to a decrease of CNY 20,294,770.54 in the same period last year[8] - Total cash and cash equivalents at the end of Q1 2024 reached ¥694,758,375.54, up from ¥99,070,915.70 at the end of Q1 2023, reflecting a net increase of ¥54,495,877.02 during the quarter[24] - The company reported a cash flow from financing activities net increase of ¥31,125,241.77 in Q1 2024, compared to a net increase of ¥40,727,861.27 in Q1 2023, showing a decrease in financing activity[24] Assets and Liabilities - Total assets increased by 3.17% to CNY 2,059,975,220.03 compared to CNY 1,996,714,366.68 at the end of the previous year[5] - The company’s total liabilities increased to CNY 1.02 billion from CNY 1.00 billion, reflecting a growth of approximately 2.0%[17] - The company’s equity attributable to shareholders reached CNY 1.04 billion, up from CNY 0.99 billion, indicating an increase of about 5.1%[17] - The company’s short-term borrowings increased by 41.58% to CNY 154,471,657.31, attributed to new bank loans[8] - Total liabilities as of Q1 2024 were CNY 733,953,963.45, an increase from CNY 667,983,925.64 in the previous year[21] Operational Efficiency - The company received government subsidies amounting to CNY 230,391.82 during the quarter, contributing to its financial performance[6] - The company reported a significant increase in cash received from sales of goods and services, amounting to CNY 257,093,414.86 in Q1 2024, compared to CNY 160,497,602.16 in Q1 2023[23] - Cash outflow from investing activities was ¥14,128,274.13 in Q1 2024, compared to ¥6,989,528.60 in Q1 2023, indicating increased investment in long-term assets[24] - The total cash outflow for operating activities was ¥231,936,380.70 in Q1 2024, slightly higher than ¥222,308,567.50 in Q1 2023, indicating stable operational costs[24] Changes in Accounting and Reporting - The company did not undergo an audit for the Q1 2024 report, which may affect the perception of financial reliability[26] - The company has adopted new accounting standards starting from 2024, which may impact future financial reporting and analysis[25] Research and Development - Research and development expenses for Q1 2024 were CNY 5,265,641.53, down from CNY 7,160,670.59 in Q1 2023, a decrease of 26.5%[21]

四川港通医疗设备集团股份有限公司 2023 年度董事会工作报告 2023 年，四川港通医疗设备集团股份有限公司（以下简称"公司"）董事会 严格按照《公司法》《证券法》等法律法规和《公司章程》《股东大会议事规则》 《董事会议事规则》等制度的规定，本着对公司和全体股东负责的态度，勤勉尽 责履行职责和义务，保障公司规范运作，促进公司持续健康稳定的发展，切实维 护公司和全体股东的利益。现将公司 2023 年度董事会工作情况汇报如下： 一、2023 年度总体经营情况 （一）公司治理基本情况 公司严格按照相关法律、法规的要求，不断完善法人治理结构，健全公司内 部控制制度，进一步规范公司运作，提高公司治理水平，严格进行信息披露工作， 有效维护了公司和投资者的利益。 （二）董事会运作情况 2023 年度，公司共召开 8 次董事会会议，董事会的召集、召开程序合法、合 规，董事会成员勤勉、认真地履行法律法规规定的职责和义务。 （三）董事会对股东大会决议的执行情况 2023 年度，公司共召开 4 次股东大会，公司董事会严格按照股东大会的决 议及授权，认真执行了股东大会审议通过的各项决议。 （四）董事会专门委员会召开情况 2023 ...

四川港通医疗设备集团股份有限公司 二 0 二三年度 审计报告 致同会计师事务所（特殊普通合伙） 目 录 | 审计报告 | 1-6 | | --- | --- | | 合并及公司资产负债表 | 1-2 | | 合并及公司利润表 | 3 | | 合并及公司现金流量表 | 4 | | 合并及公司股东权益变动表 | 5-8 | | 财务报表附注 | 9-96 | 四川港通医疗设备集团股份有限公司 财务报表附注 2023 年度（除特别注明外，金额单位为人民币元） 致同会计师事务所（特殊普通合伙） 审计报告 中国北京朝阳区建国门外大街 22 号 赛特广场 5 层邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 致同审字（2024）第 510A013317 号 四川港通医疗设备集团股份有限公司全体股东： 一、审计意见 我们审计了四川港通医疗设备集团股份有限公司（以下简称港通医疗公司）财务 报表，包括 2023 年 12 月 31 日的合并及公司资产负债表，2023 年度的合并及公司利润 表、合并及公司现金流量表、合并及公司股东权益变 ...

四川港通医疗设备集团股份有限公司 2023 年度募集资金存放与使用情况的专项报告 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求（2022 年修订）》和《深圳证券交易所上市公司自律监管指引第 2 号-创业板上 市公司规范运作》有关规定，现将本公司 2023 年度募集资金存放与使用情况说 明如下： 一、募集资金基本情况 | | 单位：万元 | | --- | --- | | 募集资金净额 | 68,999.60 | | 加：募集资金利息收入及理财收益 | 252.94 | | 减：直接投入募投项目支出 | 16,775.87 | | 减：置换预先投入募投项目的自筹资金 | 2,369.43 | | 减：超募资金永久性补充流动资金 | 800.00 | | 减：银行手续费 | 0.06 | | 期末募集资金余额 | 49,307.17 | | 其中：使用暂时闲置募集资金进行现金管理余额 | 36,100.00 | | 募集资金专户实际存放余额 | 13,207.17 | 注：上述现金管理的产品为定期存款及结构性存款。 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会证监许 ...

证券代码：301515 证券简称：港通医疗 公告编号：2024-017 四川港通医疗设备集团股份有限公司 关于续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 四川港通医疗设备集团股份有限公司（以下简称"公司"）于 2024 年 4 月 22 日召开第四届董事会第十四次会议、第四届监事会第十四次会议，审议通过 《关于续聘会计师事务所的议案》，本议案尚需提交公司股东大会审议。现将相 关事宜公告如下： 一、拟续聘会计师事务所的基本情况 （一）机构信息 1.基本信息 会计师事务所名称：致同会计师事务所（特殊普通合伙）（以下简称"致同 会所"） 成立日期：1981 年【工商登记：2011 年 12 月 22 日】 注册地址：北京市朝阳区建国门外大街 22 号赛特广场五层 首席合伙人：李惠琦 截至 2023 年末，致同会所从业人员近六千人，其中合伙人 225 名，注册会 计师 1,364 名，签署过证券服务业务审计报告的注册会计师超过 400 人。 致同会所 2022 年度业务收入 26.49 亿元（264,910.14 万元），其中审计业务 收 ...

在2023年度任职期间，本人作为公司独立董事、董事会审计委员会委员、提 名委员会主任委员，按照《公司章程》《独立董事工作制度》及公司专门委员会 工作细则等相关制度，在公司的充分配合下，勤勉尽责地履行了相关职责。 三、2023年度履职重点关注事项的情况 （一）定期报告相关事项 四川港通医疗设备集团股份有限公司 2023年度独立董事年度述职报告 根据《公司法》《证券法》《上市公司治理准则》等法律法规及《公司章程 》《独立董事工作制度》等规定，就2023年8月30日至2023年12月31日期间，本 人陈启明任职四川港通医疗设备集团股份有限公司（以下简称"公司"）独立董 事的履职情况做述职报告。具体如下： 一、个人基本情况 姚刚，男，中国国籍，1976年11月出生，工商管理硕士。2023年8月30日至 今，担任公司独立董事，任职期间不存在影响独立性的情形。 二、2023年度履职概况 在2023年度任职期间，本人应出席公司董事会会议2次，股东大会会议1次， 本人均亲自出席了上述会议。本人对提交董事会的全部议案均投出赞成票，没有 出现反对票和弃权票。 在2023年度任职期间，公司编制并披露了《2023年第三季度报告》。作 ...